Search bioRxiv⌕ Search

Biology subjects

Brochado, A. R.

Publications and source records attributed to Brochado, A. R..

9 recordsLinked to original sources

Human-targeted drugs impact antibiotic sensitivity and growth of Campylobacter jejuni

Antibiotic resistance is increasingly recognized as a major threat to global health, yet the contribution of non-antibiotics to this problem remains poorly defined. Here, we established a transcriptional chemical genomics approach to map how 2,415 host-relevant small molecules influence stress-responsive promoters and fitness of the foodborne pathogen Campylobacter jejuni. This screen uncovered widespread activation of the CmeABC efflux pump by diverse compounds, including several human-targeted drugs. Notably, ibuprofen, one of the most widely used non-steroidal anti-inflammatory drugs worldwide, induced efflux pump expression and thereby enhanced bacterial tolerance to ciprofloxacin. We also identified multiple commensal-sparing human-targeted drugs with growth-inhibitory activity against C. jejuni, highlighting opportunities for pathogen-targeted drug repurposing. Together, our findings reveal that non-antibiotic drugs can both promote resistance-associated phenotypes and selectively suppress pathogen growth. This underscores the need to consider collateral drug effects on bacterial physiology when designing strategies to curb the burden of antimicrobial resistance.

microbiology↗

Human-targeted drugs extensively reshape regulatory networks controlling virulence and antibiotic resistance in Salmonella Typhimurium

Human-targeted drugs are increasingly recognized to affect bacterial physiology, yet their impact beyond growth inhibition, and the underlying molecular mechanisms, remain poorly understood. Here, we systematically mapped how chemically diverse host-associated compounds influence virulence and intrinsic antibiotic resistance in Salmonella enterica serovar Typhimurium. Using a high-throughput reporter approach, we quantified transcriptional response of 26 key stress promoters in Salmonella against 2,415 compounds, including FDA-approved drugs, food-derived molecules, and human metabolites. We found that non-antibiotic compounds induce transcriptional responses distinct from those elicited by antibiotics, uncovering a regulatory shift from general stress responses to compound-specific regulation driven by ligand-responsive MarR- and TetR-family regulators. In particular, more than 200 non-antibiotic drugs modulate virulence or intrinsic resistance pathways through the central regulators SlyA or RamR, respectively. By integrating our large-scale dataset with machine learning, we further defined chemical features associated with ramA transcriptional activation in Salmonella, and predicted ~200 additional candidate inducers of intrinsic antibiotic resistance in this pathogen. Together, our results uncovered a large and previously unrecognized chemical landscape that reshapes bacterial stress responses through ligand-responsive regulatory mechanisms, with implications for how host-associated compounds influence pathogen virulence and antibiotic resistance.

microbiology↗

Statistical end-to-end analysis of large-scale microbial growth data with DGrowthR

Quantitative analysis of microbial growth curves is essential for understanding how bacterial populations respond to environmental cues. Traditional analysis approaches make parametric assumptions about the functional form of these curves, limiting their usefulness for studying conditions that distort standard growth curves. In addition, modern robotics platforms enable the high-throughput collection of large volumes of growth data, thus requiring strategies that can analyze large-scale growth data in a flexible and efficient manner. Here, we introduce DGrowthR, a statistical R framework and standalone app with a no-code interface for the integrative analysis of large growth experiments. DGrowthR comprises methods for data pre-processing and standardization, exploratory functional data analysis, and non-parametric modeling of growth curves using Gaussian Process regression. Importantly, DGrowthR includes a rigorous statistical testing framework for differential growth (DG) analysis. To illustrate the range of application scenarios of DGrowthR, we analyzed three large-scale bacterial growth datasets targeting distinct scientific inquiries. On an in-house dataset comprising more than 20, 000 growth curves of two pathogens that were subjected to chemical perturbations, DGrowthR enabled the discovery of compounds with significant growth inhibitory effects as well as compounds that induce non-canonical growth dynamics. On two publicly available perturbation datasets (> 100, 000 growth curves), DG analysis recovered reported adjuvants and antagonists of antibiotic activity, as well as bacterial genetic factors that determine susceptibility to specific antibiotic treatments. We anticipate DGrowthR to streamline the analysis of high-volume growth experiments, enabling researchers to make biological discoveries in a standardized and reproducible manner.

microbiology↗

Systematic Characterization of Transport Regulation in Escherichia coli across defined environmental cues

Transport of small molecules across the bacterial cell envelope is essential to ensure nutrient uptake and protect bacteria from toxic compounds. Due to its decisive role, transport is controlled by complex regulatory networks, knowledge of which - in particular across external cues - remains poorly understood. Here we investigate transcriptional regulation of seven prominent transport genes in Escherichia coli across 94 defined chemical cues, and simultaneously map the contributions of the key regulators MarA, SoxS and Rob to promoter activity. One third of all tested compounds triggered transcriptional changes, the vast majority of which previously unknown. Importantly, we exposed main drivers of transport control in E. coli, e.g. bacteriostatic, but not bactericidal, antibiotics trigger expression of efflux pumps, and that Rob contributes to [~]1/3 of all measured transcriptional changes, thereby emerging as a more prominent transport regulator than previously thought. We showcase the potential of our resource by elucidating the molecular mechanism of antibiotic antagonisms with widely consumed caffeine in E. coli. Altogether, our resource capitalizes on providing a quantitative overview of transport determinants across environments, and brings perspective to long-term prevailing concepts in the field.

microbiology↗

Pre-trained molecular representations enable antimicrobial discovery

The rise in antimicrobial resistance poses a worldwide threat, reducing the efficacy of common antibiotics. Determining the antimicrobial activity of new chemical compounds through experimental methods is still a time-consuming and costly endeavor. Compound-centric deep learning models hold the promise to speed up this search and prioritization process. Here, we introduce a lightweight computational strategy for antimicrobial discovery that builds on MolE(Molecular representation through redundancy reduced Embedding), a deep learning framework that leverages unlabeled chemical structures to learn task-independent molecular representations. By combining MolE representation learning with experimentally validated compound-bacteria activity data, we design a general predictive model that enables assessing compounds with respect to their antimicrobial potential. The model correctly identified recent growth-inhibitory compounds that are structurally distinct from current antibiotics and discovered de novo three human-targeted drugs as Staphylococcus aureus growth inhibitors which we experimentally confirmed. Our framework offers a viable cost-effective strategy to accelerate antibiotics discovery.

microbiology↗

Emergence of community behaviors in the gut microbiota upon drug treatment

Pharmaceuticals can directly inhibit the growth of gut bacteria, but the degree such interactions manifest in complex community settings is an open question. Here we compared the effects of 30 drugs on a 32-species synthetic community with their effects on each community member in isolation. While most individual drug-species interactions remained the same in the community context, communal behaviors emerged in 26% of all tested cases. Cross-protection, during which drug-sensitive species became protected in community, was 6-times more frequent than cross-sensitization, the converse phenomenon. Cross-protection decreased and cross-sensitization increased at higher drug concentrations, suggesting that the resilience of microbial communities can collapse when perturbations get stronger. By metabolically profiling drug-treated communities, we showed that both drug biotransformation and bioaccumulation contribute mechanistically to communal protection. As a proof-of-principle, we molecularly dissected a prominent case: species expressing specific nitroreductases degraded niclosamide, thereby protecting both themselves and sensitive community members.

microbiology↗

The antiphage defense system CBASS controls resistance and enables killing by antifolate antibiotics in Vibrio cholerae

Toxic bacterial modules, in particular toxin-antitoxin (TA) systems, have been long sought-after for their antimicrobial potential, although with limited success1-6. Here we show that the cyclic-oligonucleotide-based antiphage signaling system (CBASS), another example of a toxic module, increases sensitivity to well-established antifolate antibiotics, interferes with their synergy, and ultimately enables bacterial lysis by antifolates - classic bacteriostatic antibiotics, in Vibrio cholerae. We propose a molecular mechanism for the CBASS-antifolate interaction based on onset of cyclic-oligonucleotide production by the nucleotidyltransferase DncV upon folate depletion by antifolates. CBASS-antifolate interaction is specific to CBASS systems with closely related nucleotidyltransferases and similar folate binding. Altogether, our findings illustrate that toxic modules, such as the antiphage defense CBASS system, can dramatically impact antibiotic activity, and open the possibility that endogenous metabolites could also act as triggers/silencers of toxic modules under stress beyond antibiotic treatment, such as during phage infection, biofilm formation or disease environments.

microbiology↗

High-throughput profiling of drug interactions in Gram-positive bacteria

Drug combinations present a powerful strategy to tackle antimicrobial resistance, but have not been systematically tested in many bacterial species. Here, we used an automated high-throughput setup to profile [~] 8000 combinations between 65 antibacterial drugs in three Gram-positive species: the model species, Bacillus subtilis and two prominent pathogens, Staphylococcus aureus and Streptococcus pneumoniae. Thereby, we recapitulate previously known drug interactions, but also identify ten times more interactions than previously reported in the pathogen S. aureus, including two synergies that were also effective in multi-drug resistant clinical S. aureus isolates in vitro and in vivo. Interactions were largely species-specific and mostly synergistic for drugs targeting the same cellular process, as observed also for Gram-negative species1. Yet, the dominating synergies are clearly distinct between Gram-negative and Gram-positive species, and are driven by different bottlenecks in drug uptake and vulnerabilities of their cell surface structures. To further explore interactions of commonly prescribed non-antibiotic drugs with antibiotics, we tested 2728 of such combinations in S. aureus, detecting a plethora of unexpected antagonisms that could compromise the efficacy of antimicrobial treatments in the age of polypharmacy. We uncovered even more synergies than antagonisms, some of which we could demonstrate as effective combinations in vivo against multi-drug resistant clinical isolates. Among them, we showed that the antiaggregant ticagrelor interferes with purine metabolism and changes the surface charge of S. aureus, leading to strong synergies with cationic antibiotics. Overall, this exemplifies the untapped potential of approved non-antibacterial drugs to be repurposed as antibiotic adjuvants. All data can be browsed through an interactive interface (https://apps.embl.de/combact/).

microbiology↗

Fighting the spread of antibiotic resistance with bacterial competence inhibitors

Streptococcus pneumoniae is a commensal of the human nasopharynx, but it can also cause severe life-threatening antibiotic-resistant infections. Antibiotic consumption drives the spread of resistance by inducing S. pneumoniae competence leading to the uptake of exogenous DNA and horizontal gene transfer (HGT). We have identified potent inhibitors of competence, collectively called COM-blockers. We show that COM-blockers inhibit HGT by perturbing the proton motive force, thereby disrupting the export of the peptide that regulates competence. COM-blockers do not affect growth or compromise antibiotic activity at their active concentrations, and we did not observe any resistance development against them. Used as adjuvants of antibiotics, COM-blockers provide a strategy to reduce the spread of virulence factors and antibiotic resistance in human pathogens.\n\nOne Sentence SummaryAntibiotic adjuvants block competence

microbiology↗